TY - JOUR
T1 - Epigenetic regulation in Huntington's disease
AU - Hyeon, Jae Wook
AU - Kim, Albert H.
AU - Yano, Hiroko
N1 - Funding Information:
The authors apologize for omitted references. This work was supported by the National Institutes of Health grants, R01 NS111014 (to H.Y.), R21 NS103509 (to H.Y.), R01 NS051255 (to A.H.K.), and a Pilot Project Award from the Hope Center for Neurological Disorders at Washington University (to H.Y.).
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/9
Y1 - 2021/9
N2 - Huntington's disease (HD) is a devastating and fatal monogenic neurodegenerative disorder characterized by progressive loss of selective neurons in the brain and is caused by an abnormal expansion of CAG trinucleotide repeats in a coding exon of the huntingtin (HTT) gene. Progressive gene expression changes that begin at premanifest stages are a prominent feature of HD and are thought to contribute to disease progression. Increasing evidence suggests the critical involvement of epigenetic mechanisms in abnormal transcription in HD. Genome-wide alterations of a number of epigenetic modifications, including DNA methylation and multiple histone modifications, are associated with HD, suggesting that mutant HTT causes complex epigenetic abnormalities and chromatin structural changes, which may represent an underlying pathogenic mechanism. The causal relationship of specific epigenetic changes to early transcriptional alterations and to disease pathogenesis require further investigation. In this article, we review recent studies on epigenetic regulation in HD with a focus on DNA and histone modifications. We also discuss the contribution of epigenetic modifications to HD pathogenesis as well as potential mechanisms linking mutant HTT and epigenetic alterations. Finally, we discuss the therapeutic potential of epigenetic-based treatments.
AB - Huntington's disease (HD) is a devastating and fatal monogenic neurodegenerative disorder characterized by progressive loss of selective neurons in the brain and is caused by an abnormal expansion of CAG trinucleotide repeats in a coding exon of the huntingtin (HTT) gene. Progressive gene expression changes that begin at premanifest stages are a prominent feature of HD and are thought to contribute to disease progression. Increasing evidence suggests the critical involvement of epigenetic mechanisms in abnormal transcription in HD. Genome-wide alterations of a number of epigenetic modifications, including DNA methylation and multiple histone modifications, are associated with HD, suggesting that mutant HTT causes complex epigenetic abnormalities and chromatin structural changes, which may represent an underlying pathogenic mechanism. The causal relationship of specific epigenetic changes to early transcriptional alterations and to disease pathogenesis require further investigation. In this article, we review recent studies on epigenetic regulation in HD with a focus on DNA and histone modifications. We also discuss the contribution of epigenetic modifications to HD pathogenesis as well as potential mechanisms linking mutant HTT and epigenetic alterations. Finally, we discuss the therapeutic potential of epigenetic-based treatments.
KW - DNA methyltransferases (DNMTs)
KW - Epigenetic regulation
KW - Epigenetic-based therapy
KW - Huntington's disease (HD)
KW - Neurodegeneration
KW - Transcription
UR - http://www.scopus.com/inward/record.url?scp=85107412864&partnerID=8YFLogxK
U2 - 10.1016/j.neuint.2021.105074
DO - 10.1016/j.neuint.2021.105074
M3 - Article
C2 - 34038804
AN - SCOPUS:85107412864
SN - 0197-0186
VL - 148
JO - Neurochemistry International
JF - Neurochemistry International
M1 - 105074
ER -